title: A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia.
authors.affiliation: Department of Leukemia, The University of Texas M. D. Anderson Cancer Center , Houston, TX , USA.
authors.forename: Paolo
authors.initials: P
authors.lastname: Strati
authors.forename: Wei-Gang
authors.initials: WG
authors.lastname: Tong
authors.forename: Candida
authors.initials: C
authors.lastname: Vitale
authors.forename: William G
authors.initials: WG
authors.lastname: Wierda
authors.forename: Susan
authors.initials: S
authors.lastname: O'Brien
authors.forename: Jennifer R
authors.initials: JR
authors.lastname: Brown
authors.forename: Wen-Kai
authors.initials: WK
authors.lastname: Weng
authors.forename: Thomas
authors.initials: T
authors.lastname: Kipps
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Keating
authors.forename: Alessandra
authors.initials: A
authors.lastname: Ferrajoli
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004890:Erythema / Q000139:chemically induced; D005500:Follow-Up Studies; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008875:Middle Aged; D012074:Remission Induction; D000069283:Rituximab / Q000008:administration & dosage / Q000009:adverse effects; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000069283:Rituximab; D016178:Granulocyte-Macrophage Colony-Stimulating Factor